표적치료용 동반진단 시장 보고서(2026년)

Companion diagnostics for targeted therapies are diagnostic testing methods designed to detect specific biomarkers, genetic alterations, or molecular characteristics in patients to assess their suitability and potential response to targeted treatment options. These diagnostics facilitate precision medicine by supporting evidence-based therapeutic decisions, enhancing clinical outcomes, and minimizing exposure to ineffective treatments through individualized molecular profiling. They rely on advanced molecular and analytical technologies to ensure accurate identification and interpretation of disease-associated biological markers.

The primary products of companion diagnostics for targeted therapies comprise assays, kits, and reagents; instruments and systems; and software and services. Assays, kits, and reagents refer to laboratory testing materials utilized to detect specific biomarkers for guiding targeted treatment decisions. These products are developed using technologies such as polymerase chain reaction, next-generation sequencing, immunohistochemistry, in situ hybridization, and other technologies, and they are used across indications including oncology, cardiovascular diseases, neurological diseases, infectious diseases, and other medical conditions. They are applied to sample types such as tissue samples, blood samples, and other specimen types, and they are utilized by end users including hospitals and physician laboratories, reference laboratories, pharmaceutical and biotechnology companies, and academic and research institutions.

Tariffs are influencing the companion diagnostics for targeted therapies market by driving up the expenses of imported sequencing platforms, molecular testing kits, reagents, and advanced diagnostic instruments required for precision medicine workflows. This is resulting in elevated operational expenditures and slower rollout of advanced diagnostic technologies, especially in import-dependent regions such as Asia-Pacific and Latin America. Instrument-intensive segments such as next generation sequencing systems and PCR based platforms are most impacted due to their dependence on global supply chains and specialized components. However, tariffs are also promoting localized production of diagnostic kits, regional manufacturing of reagents, and greater investment in domestic biotech ecosystems, ultimately reinforcing long-term supply chain stability and innovation capacity.

The companion diagnostics for targeted therapies market size has grown rapidly in recent years. It will grow from $5.76 billion in 2025 to $6.57 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing prevalence of cancer and chronic diseases driving demand for targeted therapies, growth of molecular diagnostic laboratory infrastructure, rising adoption of precision medicine in oncology treatment protocols, expansion of genomic sequencing research initiatives, advancement of early biomarker identification technologies.

The companion diagnostics for targeted therapies market size is expected to see rapid growth in the next few years. It will grow to $11.25 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to advancements in AI-driven diagnostic analytics and clinical decision support technologies, increasing adoption of personalized medicine across healthcare systems, growth in co-development of pharmaceutical companion diagnostics, expansion of next-generation sequencing and multi-omics platforms, and rising regulatory support for biomarker-based targeted therapy approvals. Major trends in the forecast period include AI-enabled biomarker discovery and companion diagnostic interpretation platforms, integration of multi-omics datasets for precision therapy selection, expansion of next-generation sequencing-based diagnostic workflows, increasing use of automated molecular diagnostic testing systems, and growing adoption of liquid biopsy-based companion diagnostic solutions.

The increasing adoption of precision medicine is expected to drive the growth of the companion diagnostics for targeted therapies market going forward. Precision medicine refers to a medical approach that tailors treatment based on individual patient characteristics such as genetics, biomarkers, and disease phenotypes. The demand for precision medicine is increasing due to advancements in biomarker identification and molecular diagnostics, which enable more accurate classification of respiratory conditions and targeted therapy selection. Companion diagnostics for targeted therapies support precision medicine by identifying patient-specific genetic and biomarker profiles to guide the selection of effective targeted treatments and improve outcomes with fewer adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, marking a substantial increase from the six approvals recorded in 2022. Therefore, the increasing adoption of precision medicine is driving the growth of the companion diagnostics for targeted therapies market.

Key companies operating in the companion diagnostics for targeted therapies market are focusing on the development of innovative solutions, such as next-generation sequencing (NGS)-driven genomic profiling, to enable comprehensive detection of actionable genetic mutations for precise patient stratification and targeted therapy selection. Next-generation sequencing (NGS)-driven genomic profiling is a high-throughput DNA sequencing approach that analyzes multiple genes simultaneously to detect mutations and biomarkers, enabling rapid and comprehensive identification of actionable alterations for precise targeted therapy selection and personalized treatment decisions. For example, in August 2024, Illumina Inc., a US-based DNA sequencing and array technology company, launched an expanded oncology menu for its NovaSeq X Series customers, including the high-throughput TruSight Oncology 500 HT (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 assays, designed to enable large-scale comprehensive genomic profiling. These assays are based on advanced NGS workflows that integrate optimized library preparation, high-throughput sequencing chemistry, and bioinformatics-driven variant interpretation to identify actionable genomic alterations across solid tumors and circulating tumor DNA. Key features include significantly reduced sequencing run times, expanded batch sizes for higher sample throughput, and improved sequencing economics that lower overall cost per sample while maintaining clinical-grade accuracy.

In February 2024, PathAI, a US-based AI pathology company focused on the development of and support for AI-enabled companion diagnostics for targeted therapies, collaborated with Roche Tissue Diagnostics to enhance AI-powered interpretation for companion diagnostics. Through this partnership, PathAI entered into an exclusive strategic agreement with Roche Tissue Diagnostics to design and implement artificial intelligence-driven digital pathology solutions intended to enhance the accuracy, consistency, and efficiency of tissue-based companion diagnostic workflows utilized in clinical decision-making. Roche Tissue Diagnostics is a Switzerland-based diagnostics company specializing in tissue-based cancer diagnostics and laboratory systems applied in precision medicine.

Major companies operating in the companion diagnostics for targeted therapies market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Danaher Corporation, Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Qiagen N.V., Agilent Technologies Inc., Exact Sciences Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Foundation Medicine Inc., Natera Inc., Guardant Health Inc., bioMerieux S.A., Tempus AI Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Caris Life Sciences Inc., Adaptive Biotechnologies Corporation, Personalis Inc., EntroGen Inc.

North America was the dominant region in the companion diagnostics for targeted therapies market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in companion diagnostics for targeted therapies report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the companion diagnostics for targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The companion diagnostics for targeted therapies market consists of revenues earned by entities by providing services such as biomarker identification, genetic and molecular profiling, clinical validation support, and diagnostic result interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The companion diagnostics for targeted therapies market also includes sales of laboratory consumables, analytical tools, and computational systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The companion diagnostics for targeted therapies market research report is one of a series of new reports from The Business Research Company that provides companion diagnostics for targeted therapies market statistics, including companion diagnostics for targeted therapies industry global market size, regional shares, competitors with a companion diagnostics for targeted therapies market share, detailed companion diagnostics for targeted therapies market segments, market trends and opportunities, and any further data you may need to thrive in the companion diagnostics for targeted therapies industry. This companion diagnostics for targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Companion Diagnostics For Targeted Therapies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses companion diagnostics for targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for companion diagnostics for targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The companion diagnostics for targeted therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Assays, Kits, And Reagents; Instruments And Systems; Software And Services
• 2) By Technology: Polymerase Chain Reaction; Next Generation Sequencing; Immunohistochemistry; In Situ Hybridization; Other Technologies
• 3) By Indication: Oncology; Cardiovascular Diseases; Neurological Diseases; Infectious Diseases; Other Indications
• 4) By Sample Type: Tissue Samples; Blood Samples; Other Sample Types
• 5) By End User: Hospitals And Physician Laboratories; Reference Laboratories; Pharmaceutical And Biotechnology Companies; Academic And Research Institutes
• Subsegments:
• 1) By Assays, Kits, And Reagents: Diagnostic Assays; Molecular Diagnostic Kits; Immunoassay Reagents; Sequencing Reagents; Polymerase Chain Reaction Reagents; Biomarker Detection Kits; Sample Preparation Reagents; Quality Control Reagents
• 2) By Instruments And Systems: Diagnostic Analyzers; Sequencing Systems; Polymerase Chain Reaction Systems; Automated Laboratory Instruments; Digital Pathology Systems; Flow Cytometry Systems; Imaging Systems; Data Management Systems
• 3) By Software And Services: Diagnostic Data Analysis Software; Laboratory Information Management Software; Clinical Decision Support Software; Bioinformatics Services; Data Interpretation Services; Instrument Maintenance Services; Consulting Services; Training And Support Services
• Companies Mentioned: Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd; Danaher Corporation; Abbott Laboratories; Siemens Healthineers AG; Illumina Inc.; Qiagen N.V.; Agilent Technologies Inc.; Exact Sciences Corporation; Bio-Rad Laboratories Inc.; Sysmex Corporation; Foundation Medicine Inc.; Natera Inc.; Guardant Health Inc.; bioMerieux S.A.; Tempus AI Inc.; Myriad Genetics Inc.; NeoGenomics Laboratories Inc.; Caris Life Sciences Inc.; Adaptive Biotechnologies Corporation; Personalis Inc.; EntroGen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Companion Diagnostics For Targeted Therapies Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Companion Diagnostics For Targeted Therapies Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Companion Diagnostics For Targeted Therapies Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Companion Diagnostics For Targeted Therapies Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 AI Enabled Biomarker Discovery And Companion Diagnostic Interpretation Platforms
  • 4.2.2 Integration Of Multi Omics Data For Precision Therapy Selection
  • 4.2.3 Expansion Of Next Generation Sequencing Based Diagnostic Workflows
  • 4.2.4 Increasing Adoption Of Automated Molecular Diagnostic Testing Systems
  • 4.2.5 Growing Use Of Liquid Biopsy Based Companion Diagnostic Solutions

5. Companion Diagnostics For Targeted Therapies Market Analysis Of End Use Industries

• 5.1 Hospitals And Physician Laboratories
• 5.2 Reference Laboratories
• 5.3 Pharmaceutical And Biotechnology Companies
• 5.4 Academic And Research Institutes
• 5.5 Contract Research Organizations

6. Companion Diagnostics For Targeted Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Companion Diagnostics For Targeted Therapies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Companion Diagnostics For Targeted Therapies PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Companion Diagnostics For Targeted Therapies Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Companion Diagnostics For Targeted Therapies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Companion Diagnostics For Targeted Therapies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Companion Diagnostics For Targeted Therapies Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Companion Diagnostics For Targeted Therapies Market Segmentation

• 9.1. Global Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Assays, Kits, And Reagents, Instruments And Systems, Software And Services
• 9.2. Global Companion Diagnostics For Targeted Therapies Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Polymerase Chain Reaction, Next Generation Sequencing, Immunohistochemistry, In Situ Hybridization, Other Technologies
• 9.3. Global Companion Diagnostics For Targeted Therapies Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Cardiovascular Diseases, Neurological Diseases, Infectious Diseases, Other Indications
• 9.4. Global Companion Diagnostics For Targeted Therapies Market, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tissue Samples, Blood Samples, Other Sample Types
• 9.5. Global Companion Diagnostics For Targeted Therapies Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals And Physician Laboratories, Reference Laboratories, Pharmaceutical And Biotechnology Companies, Academic And Research Institutes
• 9.6. Global Companion Diagnostics For Targeted Therapies Market, Sub-Segmentation Of Assays, Kits, And Reagents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diagnostic Assays, Molecular Diagnostic Kits, Immunoassay Reagents, Sequencing Reagents, Polymerase Chain Reaction Reagents, Biomarker Detection Kits, Sample Preparation Reagents, Quality Control Reagents
• 9.7. Global Companion Diagnostics For Targeted Therapies Market, Sub-Segmentation Of Instruments And Systems, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diagnostic Analyzers, Sequencing Systems, Polymerase Chain Reaction Systems, Automated Laboratory Instruments, Digital Pathology Systems, Flow Cytometry Systems, Imaging Systems, Data Management Systems
• 9.8. Global Companion Diagnostics For Targeted Therapies Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diagnostic Data Analysis Software, Laboratory Information Management Software, Clinical Decision Support Software, Bioinformatics Services, Data Interpretation Services, Instrument Maintenance Services, Consulting Services, Training And Support Services

10. Companion Diagnostics For Targeted Therapies Market Regional And Country Analysis

• 10.1. Global Companion Diagnostics For Targeted Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Companion Diagnostics For Targeted Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Companion Diagnostics For Targeted Therapies Market

• 11.1. Asia-Pacific Companion Diagnostics For Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Companion Diagnostics For Targeted Therapies Market

• 12.1. China Companion Diagnostics For Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Companion Diagnostics For Targeted Therapies Market

• 13.1. India Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Companion Diagnostics For Targeted Therapies Market

• 14.1. Japan Companion Diagnostics For Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Companion Diagnostics For Targeted Therapies Market

• 15.1. Australia Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Companion Diagnostics For Targeted Therapies Market

• 16.1. Indonesia Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Companion Diagnostics For Targeted Therapies Market

• 17.1. South Korea Companion Diagnostics For Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Companion Diagnostics For Targeted Therapies Market

• 18.1. Taiwan Companion Diagnostics For Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Companion Diagnostics For Targeted Therapies Market

• 19.1. South East Asia Companion Diagnostics For Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Companion Diagnostics For Targeted Therapies Market

• 20.1. Western Europe Companion Diagnostics For Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Companion Diagnostics For Targeted Therapies Market

• 21.1. UK Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Companion Diagnostics For Targeted Therapies Market

• 22.1. Germany Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Companion Diagnostics For Targeted Therapies Market

• 23.1. France Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Companion Diagnostics For Targeted Therapies Market

• 24.1. Italy Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Companion Diagnostics For Targeted Therapies Market

• 25.1. Spain Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Companion Diagnostics For Targeted Therapies Market

• 26.1. Eastern Europe Companion Diagnostics For Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Companion Diagnostics For Targeted Therapies Market

• 27.1. Russia Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Companion Diagnostics For Targeted Therapies Market

• 28.1. North America Companion Diagnostics For Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Companion Diagnostics For Targeted Therapies Market

• 29.1. USA Companion Diagnostics For Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Companion Diagnostics For Targeted Therapies Market

• 30.1. Canada Companion Diagnostics For Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Companion Diagnostics For Targeted Therapies Market

• 31.1. South America Companion Diagnostics For Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Companion Diagnostics For Targeted Therapies Market

• 32.1. Brazil Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Companion Diagnostics For Targeted Therapies Market

• 33.1. Middle East Companion Diagnostics For Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Companion Diagnostics For Targeted Therapies Market

• 34.1. Africa Companion Diagnostics For Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Companion Diagnostics For Targeted Therapies Market, Segmentation By Product, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Companion Diagnostics For Targeted Therapies Market Regulatory and Investment Landscape

36. Companion Diagnostics For Targeted Therapies Market Competitive Landscape And Company Profiles

• 36.1. Companion Diagnostics For Targeted Therapies Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Companion Diagnostics For Targeted Therapies Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Companion Diagnostics For Targeted Therapies Market Company Profiles
  • 36.3.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

37. Companion Diagnostics For Targeted Therapies Market Other Major And Innovative Companies

• Illumina Inc., Qiagen N.V., Agilent Technologies Inc., Exact Sciences Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Foundation Medicine Inc., Natera Inc., Guardant Health Inc., bioMerieux S.A., Tempus AI Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Caris Life Sciences Inc., Adaptive Biotechnologies Corporation, Personalis Inc., EntroGen Inc.

38. Global Companion Diagnostics For Targeted Therapies Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Companion Diagnostics For Targeted Therapies Market

41. Companion Diagnostics For Targeted Therapies Market High Potential Countries, Segments and Strategies

• 41.1 Companion Diagnostics For Targeted Therapies Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Companion Diagnostics For Targeted Therapies Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Companion Diagnostics For Targeted Therapies Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer